1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Can Lynparza Hold On As PARP Inhibitors Enter First-Line Prostate Cancer Market?

 
• By Alaric DeArment

AstraZeneca, Pfizer and Johnson & Johnson are presenting Phase III data for PARP inhibitors combined with anti-androgen drugs in first-line mCRPC, a potential blockbuster opportunity.

AZ Cambridge campus
AstraZeneca - along with Pfizer and J&J - presented Phase III PARP inhibitor data in first-line prostate cancer at ASCO GU • Source: Shutterstock

Data from three Phase III studies presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) give a preview of what is set to become a highly competitive field for PARP inhibitors combined with anti-androgen drugs in first-line metastatic castration-resistant prostate cancer (mCRPC). With its more established position in the field, AstraZeneca PLC’s Lynparza (olaparib) may retain a competitive edge, but the space looks likely to become a three-way competition between it, Pfizer Inc.’s Talzenna (talazoparib) and Johnson & Johnson/GSK plc’s Zejula (niraparib).

ASCO GU included presentations on 16 February from three Phase III studies in particular: the PROpel trial of Lynparza combined with J&J’s Zytiga (abiraterone acetate) and prednisone or prednisolone; the TALAPRO-2 study of Talzenna with Pfizer’s Xtandi (enzalutamide); and the MAGNITUDE study of Zejula/Zytiga, which J&J’s Janssen

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

More from Therapy Areas